Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AORT

AORT - Artivion, Inc. Stock Price, Fair Value and News

23.19USD+0.02 (+0.09%)Market Closed

Market Summary

AORT
USD23.19+0.02
Market Closed
0.09%

AORT Alerts

  • Big jump in Earnings (Y/Y)

AORT Stock Price

View Fullscreen

AORT RSI Chart

AORT Valuation

Market Cap

967.8M

Price/Earnings (Trailing)

-100.55

Price/Sales (Trailing)

2.63

EV/EBITDA

24.4

Price/Free Cashflow

85.74

AORT Price/Sales (Trailing)

AORT Profitability

EBT Margin

0.03%

Return on Equity

-3.26%

Return on Assets

-1.23%

Free Cashflow Yield

1.17%

AORT Fundamentals

AORT Revenue

Revenue (TTM)

368.2M

Rev. Growth (Yr)

17.06%

Rev. Growth (Qtr)

4.02%

AORT Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

155.67%

Earnings Growth (Qtr)

289.51%

Breaking Down AORT Revenue

Last 7 days

-0.8%

Last 30 days

-1.0%

Last 90 days

12.1%

Trailing 12 Months

45.0%

How does AORT drawdown profile look like?

AORT Financial Health

Current Ratio

6.04

Debt/Equity

1.06

Debt/Cashflow

0.06

AORT Investor Care

Shares Dilution (1Y)

2.10%

Diluted EPS (TTM)

-0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024368.2M000
2023319.8M328.7M339.7M354.0M
2022305.0M309.2M313.8M313.8M
2021257.9M280.3M287.3M298.8M
2020275.1M257.8M255.0M253.2M
2019268.4M271.0M274.3M276.2M
2018206.6M227.3M247.9M262.8M
2017182.4M183.2M181.9M189.7M
2016155.1M166.6M175.2M180.4M
2015142.7M143.6M143.2M145.9M
2014141.0M142.1M142.9M144.6M
2013135.0M135.3M138.1M140.8M
2012121.7M125.5M129.3M131.7M
2011117.1M117.2M118.5M119.6M
20100113.3M115.0M116.6M
2009000111.7M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Artivion, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 30, 2024
hoff elizabeth a
acquired
-
-
6,289
-
May 30, 2024
ackerman thomas f
acquired
-
-
6,289
-
May 30, 2024
semedo anthony b.
acquired
-
-
6,289
-
May 30, 2024
bullock james
acquired
-
-
6,289
-
May 30, 2024
bevevino daniel j
acquired
-
-
6,289
-
May 30, 2024
borgstrom marna p
acquired
-
-
6,289
-
May 30, 2024
salveson jon w
acquired
-
-
6,289
-
May 30, 2024
burbank jeffrey h
acquired
-
-
6,289
-
May 10, 2024
holloway jean f
sold
-29,275
23.4201
-1,250
svp, general counsel

1–10 of 50

Which funds bought or sold AORT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
33,000
216,000
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.55
82,865
786,729
-%
May 16, 2024
Tidal Investments LLC
new
-
256,671
256,671
-%
May 16, 2024
COMERICA BANK
reduced
-8.42
26,943
348,569
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-265,214
-
-%
May 15, 2024
Tudor Investment Corp Et Al
sold off
-100
-1,436,000
-
-%
May 15, 2024
Engineers Gate Manager LP
reduced
-2.15
126,084
923,782
0.02%
May 15, 2024
QUADRANT CAPITAL GROUP LLC
unchanged
-
7,540
48,647
-%
May 15, 2024
MORGAN STANLEY
reduced
-1.86
6,872,030
49,438,000
-%
May 15, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
5.1
139,000
713,000
-%

1–10 of 44

Are Funds Buying or Selling AORT?

Are funds buying AORT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AORT
No. of Funds

Unveiling Artivion, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
perceptive advisors llc
5.8%
2,383,978
SC 13G
Feb 14, 2024
macquarie group ltd
7%
2,873,431
SC 13G/A
Feb 13, 2024
vanguard group inc
6.41%
2,630,873
SC 13G/A
Feb 12, 2024
morgan stanley
5.8%
2,375,713
SC 13G/A
Feb 08, 2024
wellington management group llp
5.99%
2,459,646
SC 13G/A
Jan 22, 2024
blackrock inc.
16.7%
6,844,308
SC 13G/A
Feb 14, 2023
macquarie group ltd
6.60%
2,662,637
SC 13G/A
Feb 10, 2023
wasatch advisors inc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
6.97%
2,809,140
SC 13G/A
Feb 08, 2023
morgan stanley
5.4%
2,189,557
SC 13G

Recent SEC filings of Artivion, Inc.

View All Filings
Date Filed Form Type Document
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
May 30, 2024
SD
SD
May 17, 2024
8-K
Current Report

Peers (Alternatives to Artivion, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-0.10% -2.08%
32.14
4.49
-2.84% -3.00%
67.6B
19.7B
-1.04% -9.58%
50.7
3.43
4.82% -17.56%
18.2B
3.9B
-10.79% -26.67%
39.44
4.66
5.72% 46.72%
17.2B
14.9B
-4.26% -25.60%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.60% 25.29%
31.07
2.74
6.16% 35.06%
8.7B
12.4B
-8.47% -12.48%
22.53
0.7
-0.93% -18.83%
8.2B
2.6B
-1.69% -23.28%
-25.56
3.16
-6.25% -68.58%
5.3B
3.9B
-9.26% -35.41%
-55.79
1.35
0.23% 90.80%
3.4B
387.1M
-0.06% 30.91%
-216.17
8.9
30.82% 65.57%
2.2B
6.6B
-1.48% -10.95%
12.01
0.34
1.50% -10.29%
SMALL-CAP
1.5B
3.2B
12.63% 11.29%
-2.15
0.46
7.94% -1695.32%
384.5M
169.3M
2.09% -2.41%
-5
2.27
7.49% -244.90%
226.3M
324.0M
-6.46% -49.01%
-1.18
0.7
-3.19% -337.41%
47.1M
50.5M
-15.62% -80.60%
-2.07
0.93
14.25% -10.06%
1.8M
3.7M
70.00% -81.62%
-0.15
0.48
5.77% 8.23%

Artivion, Inc. News

Latest updates
Yahoo Finance33 hours ago
MarketBeat11 May 202401:16 pm
Yahoo Finance08 May 202407:00 am
PR Newswire06 May 202407:00 am
Seeking Alpha06 May 202407:00 am

Artivion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.0%97.0094.0088.0089.0083.0079.0077.0080.0077.0079.0072.0076.0071.0068.0065.0054.0066.0070.0068.0071.0068.00
Gross Profit3.0%63.0061.0056.0058.0054.0051.0049.0052.0051.0051.0048.0051.0048.0045.0043.0036.0044.0047.0045.0047.0044.00
Operating Expenses-35.0%38.0058.0058.0065.0058.0047.0053.0048.0049.0061.0049.0049.0046.0043.0039.0038.0045.0043.0041.0040.0042.00
  S&GA Expenses-39.0%31.0050.0051.0057.0050.0038.0041.0039.0039.0051.0039.0041.0039.0036.0034.0032.0039.0038.0034.0035.0037.00
  R&D Expenses-9.1%7.008.006.007.007.008.0012.009.0010.009.0010.008.008.007.006.006.006.005.006.006.006.00
EBITDA Margin80.9%0.14*0.08*0.09*0.07*0.07*0.08*0.02*0.08*0.09*0.09*0.15*0.10*---------
Interest Expenses25.3%8.006.007.006.006.005.005.004.004.004.004.00----------
Income Taxes55.1%5.003.000.001.005.001.001.001.001.004.00-2.640.00-1.363.00-1.31-1.08-1.472.00-0.86-0.09-1.35
Earnings Before Taxes2262.6%13.00-0.59-9.42-2.66-8.923.00-12.53-3.30-2.43-16.098.00-2.18-4.50-0.09-4.18-4.77-8.132.00-0.993.00-1.65
EBT Margin100.5%0.00*-0.06*-0.05*-0.06*-0.07*-0.05*-0.11*-0.04*-0.04*-0.05*0.00*-0.04*---------
Net Income289.5%8.00-3.97-9.80-3.38-13.532.00-13.71-4.26-3.39-20.1011.00-2.18-3.14-3.46-2.87-3.69-6.66-0.68-0.133.00-0.30
Net Income Margin69.8%-0.03*-0.09*-0.07*-0.09*-0.09*-0.06*-0.13*-0.06*-0.05*-0.05*0.01*-0.04*---------
Free Cashflow-202.2%-9.109.006.005.00-8.39-2.311.00-10.13-2.84-1.85-6.18-3.10---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.1%784792775778757763743765782793819810795789782693621606593597587
  Current Assets-1.4%277281267264241247238240245248257238236235234287214187181189179
    Cash Equivalents-13.3%51.0059.0053.0049.0031.0039.0038.0040.0051.0055.0065.0051.0057.0062.0065.0012664.0034.0037.0040.0041.00
  Inventory-0.3%82.0082.0079.0078.0076.0074.0073.0074.0076.0077.0078.0076.0073.0073.0069.0063.0054.0053.0048.0045.0044.00
  Net PPE-1.5%38.0038.0037.0038.0039.0039.0036.0036.0037.0038.0037.0036.0031.0033.0032.0032.0032.0032.0030.0031.0030.00
  Goodwill-0.9%245247243246246244235241248250252255254260254186184187183188187
Liabilities-4.2%489511503495477478488483484492507509498461456397344320315315314
  Current Liabilities-20.8%46.0058.0055.0056.0044.0050.0046.0042.0043.0045.0061.0059.0058.0060.0054.0049.0044.0045.0042.0037.0036.00
  Long Term Debt2.4%313306306306306306307307307307308308310290290289244215215215215
    LT Debt, Current-81.4%0.001.002.002.002.002.002.002.002.002.002.002.001.001.001.001.001.001.001.001.001.00
    LT Debt, Non Current2.4%313306306306306306307307307307308308310290290289244215215215215
Shareholder's Equity4.7%295282272283280284255282297301312302297329326297277286278282273
  Retained Earnings15.7%-40.37-47.91-43.93-34.13-30.75-17.22-19.39-5.67-1.412.0022.0011.0014.0020.0023.0026.0030.0037.0037.0038.0035.00
  Additional Paid-In Capital2.0%363356351347343337334330327323309305301316316293274272269266262
Accumulated Depreciation--------------78.00---71.00---
Shares Outstanding1.3%41.0041.0043.0042.0040.0040.0040.0040.0040.0039.0039.0039.00---------
Float----666---725---1,070---694---1,078-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-150.7%-5,49310,8387,2326,909-6,154-2173,976-8,314-598716-2,9092,647-3,0395,4507,679-3,3952,6351,06012,8607461,161
  Share Based Compensation-12.1%3,4783,9563,1873,9383,3413,1553,0892,9343,1663,2402,8762,1152,480-5202,3582,5102,5642,2182,4622,2691,850
Cashflow From Investing-35.3%-3,611-2,669-2,0687,078-2,843-2,668-3,053-2,286-2,708-2,81215,516-6,234-810-2,346-66,301-1,578-2,903-3,190-17,107-2,219-1,427
Cashflow From Financing145.2%737-1,630-9092,2331,171-859252-797-235-8,801315-1,642-2,095-1,682-89667,67128,515-657-12.00391-1,215
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AORT Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 97,431$ 83,229
Cost of products and preservation services:  
Total cost of products and preservation services34,48529,502
Gross margin62,94653,727
Operating expenses:  
General, administrative, and marketing30,68950,365
Research and development6,9467,223
Total operating expenses37,63557,588
Operating income (loss)25,311(3,861)
Interest expense7,8266,096
Interest income(374)(75)
Loss on extinguishment of debt3,6690
Other expense (income), net1,409(963)
Income (loss) before income taxes12,781(8,919)
Income tax expense5,2484,613
Net income (loss)$ 7,533$ (13,532)
Income (loss) per share:  
Basic (in usd per share)$ 0.18$ (0.33)
Diluted (in usd per share)$ 0.18$ (0.33)
Weighted-average common shares outstanding:  
Basic (in shares)41,29040,432
Diluted (in shares)47,88640,432
Net income (loss)$ 7,533$ (13,532)
Other comprehensive (loss) income:  
Foreign currency translation adjustments(3,137)4,621
Unrealized gain (loss) from foreign currency intra-entity loans, net of tax1,609(1,005)
Comprehensive income (loss)6,005(9,916)
Products  
Revenues:  
Total revenues71,11462,291
Cost of products and preservation services:  
Total cost of products and preservation services23,75019,533
Preservation services  
Revenues:  
Total revenues26,31720,938
Cost of products and preservation services:  
Total cost of products and preservation services$ 10,735$ 9,969

AORT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 51,118$ 58,940
Trade receivables, net74,30171,796
Other receivables2,2722,342
Inventories, net81,71681,976
Deferred preservation costs, net50,15149,804
Prepaid expenses and other17,22715,810
Total current assets276,785280,668
Goodwill245,030247,337
Acquired technology, net138,474142,593
Operating lease right-of-use assets, net42,49243,822
Property and equipment, net37,78838,358
Other intangibles, net29,50629,638
Deferred income taxes6681,087
Other long-term assets13,2648,894
Total assets784,007792,397
Current liabilities:  
Accounts payable10,37813,318
Accrued compensation10,84318,715
Accrued expenses15,92612,732
Taxes payable2,0903,840
Current maturities of operating leases3,2143,395
Accrued procurement fees1,4181,439
Current portion of long-term debt2701,451
Other current liabilities1,6912,972
Total current liabilities45,83057,862
Long-term debt313,004305,531
Contingent consideration46,42063,890
Non-current maturities of operating leases42,86143,977
Deferred income taxes22,34321,851
Deferred compensation liability7,4456,760
Non-current finance lease obligation3,2683,405
Other long-term liabilities7,8517,341
Total liabilities489,022510,617
Commitments and contingencies
Shareholders’ equity:  
Preferred stock00
Common stock (75,000 shares authorized, 43,224 and 42,569 shares issued in 2024 and 2023, respectively)432426
Additional paid-in capital363,113355,919
Retained deficit(40,374)(47,907)
Accumulated other comprehensive loss(13,538)(12,010)
Treasury stock, at cost, 1,487 shares as of March 31, 2024 ‎and December 31, 2023(14,648)(14,648)
Total shareholders’ equity294,985281,780
Total liabilities and shareholders’ equity$ 784,007$ 792,397
AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
 CEO
 WEBSITEhttps://artivion.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES1300

Artivion, Inc. Frequently Asked Questions


What is the ticker symbol for Artivion, Inc.? What does AORT stand for in stocks?

AORT is the stock ticker symbol of Artivion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artivion, Inc. (AORT)?

As of Tue Jun 18 2024, market cap of Artivion, Inc. is 967.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers. The fair value of Artivion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artivion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artivion, Inc. a good stock to buy?

The fair value guage provides a quick view whether AORT is over valued or under valued. Whether Artivion, Inc. is cheap or expensive depends on the assumptions which impact Artivion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AORT.

What is Artivion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, AORT's PE ratio (Price to Earnings) is -100.55 and Price to Sales (PS) ratio is 2.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Artivion, Inc.'s stock?

In the past 10 years, Artivion, Inc. has provided 0.1 (multiply by 100 for percentage) rate of return.